NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups June 24, 2022Vol.48 No.25By Paul Goldberg and Alice Tracey
Conversation with The Cancer Letter Julie Bauman: Washington, DC, needs one more NCI-designated cancer center—and it matters that a woman runs it June 17, 2022Vol.48 No.24By Paul Goldberg
NCI Doug Lowy: NCI to fund MCED research, early-stage investigator diversity in Moonshot 2.0 June 17, 2022Vol.48 No.24By Alice Tracey
Trials & Tribulations ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV June 17, 2022Vol.48 No.24By Joel M. Palefsky and Robert Yarchoan
Lowy calls for expanding NCI’s clinical impact, including: (1) the number of drug candidates, (2) the clinical trials system, and (3) access to cancer care June 10, 2022Vol.48 No.23By Alice Tracey
Wake Forest CCSG cut from 5 years to 3 as center changes leadership, administrative structure May 27, 2022Vol.48 No.21By Paul Goldberg
Capitol Hill Cancer groups ask for $4.1 billion increase for NIH, $850 million boost for NCI in FY23 May 27, 2022Vol.48 No.21By Alice Tracey
Clinical Roundup NCI study: Cancer death rates among Black people have declined, but disparities remain May 20, 2022Vol.48 No.20
